Intangible Assets, Net (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended		12 Months Ended		0 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011	Oct. 18, 2011 Teva Pharmaceuticals, Inc. Asset Purchase Agreement [Member] products	Oct. 18, 2011 Fentanyl Citrate Lozenges And Modafinil Tablets [Member]	Oct. 18, 2011 Cyclobenzaprine ER Capsules [Member]	Oct. 18, 2011 Fentanyl Citrate Lozenges [Member] Y	Oct. 18, 2011 Modafinil Tablets [Member]
Intangible Assets [Line Items]
Amortization expense related to intangible assets			$ 22,482		$ 6,118
Intangible asset impairment	0	0	2,000	0
Intangible Assets, Number of Products						3
Cash paid to acquire rights			0	450			24,000
Payments for additional milestone launch								1,000
Payments allocation based on expected future cash flow									18,000	6,000
Remaining net book value of the intangible asset									$ 15,336
Amortization period (in years)									5